Neonatal lupus erythematosus—a rare syndrome of transient autoimmunity

Nikolina Zdraveska1 | Aco Kostovski1 | Aspazija Sofijanova1 | Snezana Jancevska2 | Jana Jovanovska1 | Milena Kacarska1 | Katerina Damevska3

1University Children Hospital, Faculty of Medicine, Ss Cyril and Methodius University in Skopje, North Macedonia
2University Clinic for Obstetrics and Gynecology, Faculty of Medicine, Ss Cyril and Methodius University in Skopje, North Macedonia
3University Clinic of Dermatology, Faculty of Medicine, Ss Cyril and Methodius University in Skopje, North Macedonia

Abstract
Neonatal lupus erythematosus (NLE) is a rare autoimmune disease due to a passive transfer of maternal autoantibodies to the fetus. The clinical spectrum is variable and includes skin lesions, cardiac, hematological, or hepatobiliary disorders. We report an NLE case presenting with skin eruption that was initially considered as tinea.

KEYWORDS
antinuclear antibodies, lupus erythematosus, neonatal lupus erythematosus, skin lesions

1 INTRODUCTION

Neonatal lupus erythematosus (NLE) is an uncommon acquired autoimmune disease caused by the passive transfer of maternal autoantibodies including anti-Sjögren’s syndrome A (Ro/SSA), anti-Sjögren’s syndrome B (La/SSB), ribonuclear protein (RNP), and antiphospholipid (APL) antibodies.1 Seropositive mothers usually have known or undiagnosed autoimmune diseases at the time of childbirth. The clinical spectrum is variable and includes skin lesions, cardiac, hematological, or hepatobiliary disorders. Skin eruptions are common in NLE. However, they are often misdiagnosed with other erythematous rashes that are frequently seen in the neonatal age such as skin infection or eczema, particularly if the mother is asymptomatic.2 It is considered that more than half of seropositive mothers are completely asymptomatic and become aware of these antibody reactivities upon detection of fetal bradycardia or neonatal skin rash appearance.2 We report a case of a female newborn referred for evaluation of annular rash on the face and trunk that was initially considered as tinea. Differential diagnoses of NLE, evolution of lesions, management, and prognosis are discussed.

2 CASE REPORT

A 3-week-old female newborn was referred for evaluation of a rash on the face and trunk initially considered as tinea. The rash had been present since 2 weeks of age and the lesions were increasing in size over the last week. Otherwise, the child appeared well and was gaining
weight adequately. The baby was born at term, by a spontaneous delivery to a 26-year-old healthy gravida 2 para 1 woman. The mother had a spontaneous abortion prior the actual pregnancy. She received routine prenatal care with all prenatal laboratory and fetal ultrasound findings within normal limits. Birthweight was 3060 g, and birth length was 50 cm. Apgar score was 8 and 9 in the first minute and the fifth minute, respectively. In the maternity hospital, the baby received antibiotic treatment for non-specific neonatal infection and was discharged on the 5th postnatal day with mild thrombocytopenia that was considered transient. Physical examination revealed skin and mucous membrane paleness and multiple annular lesions with central hypopigmentation, with dimensions 1–3 cm, solitary or conflating, mainly localized on the face, the anterior side of the chest, and abdomen (Figures 1, 2). There were no signs of inflammation or pathologic discharge. Heart rate was rhythmic; the frequency was 150/min, without any pathological murmurs. The abdomen was soft and non-tender with no hepatosplenomegaly. Initial laboratory analysis showed anemia, thrombocytopenia (Hgb 90g/L, RBC 2.88×10^{12}/l, PLT 58×10^{9}/l), and elevated serum transaminases: AST 216 U/L (normal 15–59); ALT 136 U/L (normal 9–72). The serum electrolytes, protein, albumin, blood urea nitrogen, and creatinine levels were normal.

Histological examination showed lamellar orthokeratosis, a completely flattened epidermis with vacuolar degeneration in some cells on the basal cell layer. There was massive edema in the superficial and the deeper dermis, disjunction of collagen and elastic fibers, and intense lymphocyte inflammatory infiltrate with interface distribution on some sides. Further serologic studies showed positive anti-Ro/SSA (189 U/mL, normal <20) and anti-La/SSB (240 U/mL, normal <20) antibodies. All the other antinuclear antibodies were negative, as follows:

\[
\text{anti-dsDNA<10U/mL (normal<30); nRNP/sm 3.58U/mL (normal <20); anti-Ribosomal P protein<2.09U/mL (normal <30); anti-nucleosomes<2.0U/mL (normal <20); and anti-histones 4.95U/mL (normal <30).}
\]

In addition, the maternal serologic screen for antinuclear antibodies was positive for anti-Ro/SSA and anti-La/SSB, with values of 263 U/mL and 293 U/mL, respectively. Based on the above finding, the diagnosis of NLE was made. Symptomatic treatment was provided, and hydrocortisone cream was applied on the lesions. During the follow-up, hematologic and liver tests normalized at 3 months of age, followed by clearance of cutaneous lesions and negative serology at 7 months of age.

3 | DISCUSSION

Our case fulfilled the criteria for diagnosis of cutaneous NLE accepted by the most of authors in the literature including typical lesions in the first year of life, histologic evidence of basal cell vacuolar degeneration, and mononuclear cell infiltration, and positive anti-Ro/SSA or La/SSB.

These maternally transferred autoantibodies mediate fetal autoimmune disease through the formation of antibody complexes with apoptotic antigens in the skin, liver, or heart. It is a rare condition as only 1%–2% of infants with positive maternal autoantibodies develop NLE. Conversely, about half of women with circulating autoantibodies who have children with NLE are completely asymptomatic; however, they might develop some rheumatologic disease later in life.

NLE presents mainly with cardiac, dermatologic, hepatic manifestations and less commonly with hematologic,
central nervous system, or splenic abnormalities. Its most serious complication is the atrioventricular block, which can be diagnosed in utero.

Skin lesions are common in NLE and may be present at birth or several weeks after birth. The morphology is similar to the subacute cutaneous SLE rash characterized by round, discoid, or elliptical erythematous patches or plaques with central clearing, with or without fine scale. The neonatal lupus lesions typically involve the face, scalp, neck, trunk, and extremities, and ultraviolet light (sunlight or phototherapy) frequently induces or exacerbates them. Telangiectasia is described in some cases and is considered to be the result of angiogenesis disturbances.6,7

The histopathology of the skin lesions is typical for epidermal necrosis, basal cell vacuolar degeneration at the dermo-epidermal interface, and adnexal structures. Additionally, urticaria-like lesions with superficial and deep perivascular and periaxial lymphocytic infiltrates may be present.8

The neonatal lupus rash remits within the first year in almost all cases in parallel with the clearance of maternal antibodies. Mild epidermal atrophy, telangiectases, and dyspigmentation may persist further, particularly if the skin lesions were highly inflammatory. Skin manifestation of NLE should be differentiated from various erythematous rashes seen in the neonatal period such as annular urticaria, tinea corporis, eyelid telangiectasias, erythema multiforme, congenital rubella, and congenital syphilis.8 Newborns with tinea corporis have similar skin lesions that are usually more inflammatory, as well as skin lesions in other family or contact case. In telangiectasias, there are capillary malformations on the whole skin over, not scaly, rarely multiple and tend to improve during the first weeks of life.

Treatment of NLE that affects the skin, blood, spleen, or liver is only supportive, as it is usually self-limited and resolves without intervention over time.9 For skin manifestations, topical corticosteroids have been previously evaluated; however, the efficacy has not been established. Avoidance of sun or ultraviolet light exposure to prevent or minimize the rash and residual skin abnormalities is recommended.9

The prognosis of NLE is dependent mainly on cardiac involvement; the reported mortality rate is 20% in neonates with heart block despite pacemaker implantation. Children who have had NLE may be at increased risk of developing an autoimmune or rheumatic disease. However, there were no babies with NLE nor in their siblings who developed SLE after long-term follow-up.10

On the contrary, the risk of NLE occurrence in subsequent pregnancies is up to 50% and the mothers should be carefully monitored with serial fetal echocardiograms.11

In conclusion, NLE presents a rare neonatal disease due to maternal autoimmunity, which can have various clinical presentations. Although cutaneous NLE is a transient condition, it should be recognized promptly due to the risk of recurrence in the subsequent pregnancies with more severe presentation and there is a need for careful follow-up.

AUTHOR CONTRIBUTIONS
NZ had main contribution in literature search, writing and drafting the manuscript. NZ, AS, SJ, JJ, and MK contributed in the diagnosing, treatment, and follow-up of the patient. AK was consultant regarding hepatic involvement. KD performed and interpreted the skin biopsy. NZ, AK, AS, SJ, and KD edited the manuscript. All authors approved the final version.

ACKNOWLEDGMENT
None.

CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available on request from the corresponding author.

CONSENT
Written informed consent was obtained from the patient’s parent to publish this report in accordance with the journal’s patient consent policy.

ORCID
Nikolina Zdraveska © https://orcid.org/0000-0001-5318-9554

REFERENCES
1. Vanoni F, Lava SAG, Fossali EF, et al. Neonatal systemic lupus erythematosus syndrome: a comprehensive review. Clin Rev Allergy Immunol. 2017;53(3):469–476.
2. Rivera TL, Izmirly PM, Birnbaum BK, et al. Disease progression in mothers of children enrolled in the research registry for neonatal lupus. Ann Rheum Dis. 2009;68(6):828–835.
3. Izmirly PM, Halushka MK, Rosenberg AZ, et al. Clinical and pathologic implications of extending the spectrum of maternal autoantibodies reactive with ribonucleoproteins associated with cutaneous and now cardiac neonatal lupus from SSA/Ro and SSB/La to U1RNP. Autoimmun Rev. 2017;16(9):980–983.
4. Tran HB1, Macardle PJ, Hiscock J, et al. Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arthritis Rheum. 2002;46:1572–1579.
5. Wisuthsarewwong W, Soongswang J, Chantor R. Neonatal lupus erythematosus: clinical character, investigation, and outcome. Pediatr Dermatol. 2011;28(2):115-121.
6. Neiman A, Lee L, Weston W, Buyon J. Cutaneous manifestations of neonatal lupus without heart block: characteristics of mothers and children enrolled in a national registry. *J Pediatr*. 2000;137:674-680.

7. Savino F, Viola S, Tarasco V, Locatelli E, Ricagni A, Coppo P. Neonatal lupus erythematosus: a cutaneous cases based update. *Ital J Pediatr*. 2016;42:1.

8. Penate Y1, Guillermo N, Rodriguez J, et al. Histopathologic characteristics of neonatal cutaneous lupus erythematosus: description of five cases and literature review. *J Cutan Pathol*. 2009;36:660-667.

9. Izmirly PM, Llanos C, Lee LA, Askanase A, Kim MY, Buyon JP. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. *Arthritis Rheum*. 2010;62:1153-1157.

10. Martin V1, Lee LA, Askanase AD, Katholi M, Buyon JP. Long-term follow-up of children with neonatal lupus and their unaffected siblings. *Arthritis Rheum*. 2002;46:2377-2383.

11. Derdulska JM, Rudnicka L, Szykut-Badaczewska A, et al. Neonatal lupus erythematosus - practical guidelines. *J Perinat Med*. 2021;49:529-538. doi:10.1515/jpm-2020-0543

**How to cite this article:** Zdraveska N, Kostovski A, Sofijanova A, et al. Neonatal lupus erythematosus—a rare syndrome of transient autoimmunity. *Clin Case Rep*. 2022;10:e06004. doi: [10.1002/ccr3.6004](https://doi.org/10.1002/ccr3.6004)